Stock AnalizHCA Healthcare (HCA) earnings for the quarter ended September 2026: EPS beats estimates
HCA Healthcare reported results for the quarter ended September 2026 on October 27, 2026. Adjusted earnings per share came in at $7.22 against the analysts’ average forecast of $6.63, a beat of 8.9%.
Revenue for the quarter was $19.85 billion, up 3.6% from $19.16 billion in the same quarter a year earlier.
The market’s verdict: the stock fell 3.3% on the first trading day after the report.
The last four quarters
HCA Healthcare has beaten the analysts’ EPS forecast in 4 of the last 4 quarters.
| Quarter | EPS | Forecast | Surprise | Revenue growth | Price reaction |
|---|---|---|---|---|---|
| Sep 2026 | $7.22 | $6.63 | +8.9% | +4% | −3.3% |
| Jun 2026 | $7.59 | $7.50 | +1.2% | — | +3.5% |
| Mar 2026 | $7.15 | $7.13 | +0.3% | +4% | −6.0% |
| Dec 2025 | $8.01 | $7.48 | +7.1% | +7% | +4.0% |
What comes next
Analysts expect EPS of $8.19 for the next quarter on average and $30.05 for the fiscal year ending December 31, 2026.
The average analyst price target is $483.41, 3% below the current price of $499.05.
Valuation and score
HCA Healthcare scores 3.0 out of 5 overall on Stock Analiz (good, with some weak spots), trades at a trailing P/E of about 16.6, and its intrinsic value under moderate assumptions is about 3% above the current market value. Full HCA Healthcare analysis with 10 years of financials
Frequently asked questions
What was HCA Healthcare’s EPS for the quarter ended September 2026?
$7.22 adjusted per share, against an analyst consensus of $6.63.
How much revenue did HCA Healthcare report?
$19.85 billion, up 3.6% year over year.
More
This report was written automatically from the published numbers within hours of the release. It is information, not investment advice.